ITOG Opens First Clinical Trial

ITOG opened its first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib.

NCI9312/OSU12154/RU2412101 is an investigator-initiated, multi-center, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first clinical trial will be coordinated by the Academic and Community Cancer Research United (ACCRU) and is funded by Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI). Additional funding for the clinical trial and correlative science is provided by ITOG, which is a 501(c)(3) tax-exempt public charity. ITOG’s mission is to catalyze a cure for thyroid cancer.

Led by Ohio State University Comprehensive Cancer Center, this study will also open at Massachusetts General Hospital, Mayo Clinic (Jacksonville and Rochester), MD Anderson Cancer Center, Roswell Park Cancer Institute and University of Chicago.

Cabozantinib is an oral multikinase inhibitor targeting several angiogenic proteins such as VEGFR, PDGFR, c-met as well as RET kinase. It was recently approved by the Food and Drug Administration of United States for patients with progressive medullary thyroid cancer. ITOG is testing this drug for its use in a 2nd line setting for patients with DTC who progress on first line VEGFR targeted therapy. Given that c-met is thought to be critical in causing failure of VEGFR targeted therapy, cabozantinib is chosen for testing in 2nd line setting due to its unique activity against c-met. During the trial, the study drug will be administered orally once daily until cancer progression or intolerance. The study will also examine if this drug is effective against bony metastasis.

Interested in Participating?

Eligible patients will be required to have locally advanced or metastatic, radioiodine-refractory DTC, measurable disease, progression on exactly one line of prior VEGFR-targeted therapy (including but not limited to sorafenib, sunitinib, vandetanib, pazopanib, or lenvatinib) within 24 weeks prior to study entry. More information related to trial is available at http://clinicaltrials.gov/ct2/show/NCT01811212?term=cabozantinib+in+thyroid&rank=2

For questions related to trial please contact Manisha H. Shah, MD at 614-293-4680 or manisha.shah@osumc.edu
ITOG Annual Meeting:
The “Go To” Meeting for Thyroid Cancer

ITOG held its 2013 Annual Meeting in Rochester, Minnesota at Mayo Medical Center on April 28-30th. The meeting was hosted by ITOG Board Members Drs. Keith Bible and Robert Smallridge. Highlights from the meeting included scientific sessions on Molecular Therapeutic Approaches to Thyroid Cancer. Dr. Steve Russell outlined his program for developing oncolytic viruses and described the efforts to bring these to the clinic. ITOG members had an orientation and overview of ACCRU, which included tours of Mayo/ACCRU research laboratories and specimen handling/archiving facilities. Scientific sessions included presentations highlighting preclinical models of thyroid cancer and discussion of future trials including novel agents for differentiated and medullary thyroid cancer. ITOG members had dinner at the Mayo Foundation House (pictured), the former home of Dr. and Mrs. William Mayo. ITOG elected three new members to its Board of Directors: Dr. Michael Tuttle, Dr. Rossella Elisei, and Dr. Yuri Nikiforov and Dwight Vicks was re-elected to the Board. The meeting allowed participants to develop and plan new collaborations and clinical trials for thyroid cancer patients.

Please visit our new website www.itog.org or contact Dwight Vicks at dwight@itog.org
ITOG Members

Richard Abrams
Douglas Ball, M.D.
Eric Baudin, M.D. Ph.D.
Victor Bernet, M.D.
Keith Bible, M.D.
Glenn Braunstein, M.D.
James Brierley, M.B. B.S.
Marcia Brose, M.D.
Kenneth Burman, M.D.
Naifa Busaidy, M.D.
Maria Cabanillas, M.D.
Ross Cagan, Ph.D.
Herbert Chen, M.D.
Ezra Cohen, M.D.
John Copland, Ph.D.
Gilbert Cote, Ph.D.
Gilbert Daniels, M.D.
Michael Demeure, M.D.
Rossella Elisei, M.D.
James Fagin, M.D.
Thomas Fahey III, M.D.
Sebastiano Filetti, M.D.
Robert Gagel, M.D.
Ronald Ghossein, M.D.
Andrew Gianoukakis, M.D.
Ann Gramza, M.D.
Bryan Haugen, M.D.
Alan Ho, M.D. Ph.D.
Yariv Houvras, M.D.
Sissy Jhiang, Ph.D.
Richard Kloos, M.D.
Monika Krzyzanowska, M.D.
Sophie Lebouilieux, M.D.
Michael Menefee, M.D. Ph.D.
Jeffrey Moley, M.D.
Barry Nelkin, Ph.D.
Yuri Nikiforov, M.D. Ph.D.
Furio Pacini, M.D.
Sareh Parangi, M.D.
David Pfister, M.D.
Matthew Ringel, M.D.
Bruce Robinson, M.D.
Massimo Santoro, Ph.D.
Annie Sawka, M.D.
Martin Schlumberger, M.D.
Rebecca Schweppe, Ph.D.
Manisha Shah, M.D.
Eric Sherman, M.D.
Steven Sherman, M.D.
Robert Smallridge, M.D.
Julie Ann Sosa, M.D.
Richard Tantillo
R. Michael Tuttle, M.D.
Dwight Vicks
Samuel Wells, M.D.
Lori Wirth, M.D.
Mingxhao Xing, M.D.

Johns Hopkins
Institut Gustave Roussy
Mayo Clinic (Jacksonville)
Mayo Clinic (Rochester)
Cedars Sinai Medical Center
Princess Margaret Hospital
University of Pennsylvania
Washington Hospital Center
MD Anderson Cancer Center
MD Anderson Cancer Center
Mount Sinai School of Medicine
University of Wisconsin
University of Chicago
Mayo Clinic (Jacksonville)
MD Anderson Cancer Center
Massachusetts General Hospital
Scottsdale Healthcare
University of Pisa
Memorial Sloan-Kettering
Weill Cornell Medical Center
Universita’ degli Studi di Roma
MD Anderson Cancer Center
Memorial Sloan-Kettering
University of California LA
National Cancer Institute
University of Colorado
Memorial Sloan-Kettering
Weill Cornell Medical Center
Ohio State University
Veracyte
Princess Margaret Hospital
Institut Gustave Roussy
Mayo Clinic (Jacksonville)
Washington University
Johns Hopkins
University of Pittsburg
University of Siena
Harvard Medical School
Memorial Sloan-Kettering
Ohio State University
University of Sydney
University Federico II of Naples
University of Toronto
Institut Gustave Roussy
University of Colorado
Ohio State University
Memorial Sloan-Kettering
MD Anderson Cancer Center
Mayo Clinic (Jacksonville)
Duke University
Hamilton College
Memorial Sloan-Kettering
National Cancer Institute
Massachusetts General Hospital
Johns Hopkins

Patient Advocate
Endocrinology
Endocrinology
Endocrinology
Medical Oncology
Endocrinology
Radiation Oncology
Medical Oncology
Endocrinology
Endocrinology
Endocrinology
Basic Science
Surgical Oncology
Medical Oncology
Basic Science
Basic Science
Endocrinology
Surgical Oncology
Endocrinology
Endocrinology
Endocrinology
Endocrinology
Pathology
Endocrinology
Medical Oncology
Endocrinology
Medical Oncology
Basic Science
Endocrinology
Medical Oncology
Endocrinology
Basic Science
Pathology
Endocrinology
Surgical Oncology
Medical Oncology
Endocrinology
Endocrinology
Basic Science
Endocrinology
Medical Oncology
Endocrinology
Basic Science
Endocrinology
Basic Science
Endocrinology
Medical Oncology
Endocrinology
Endocrinology
Surgical Oncology
Patient Advocate
Endocrinology
Treasurer
Surgical Oncology
Medical Oncology
Endocrinology
ITOG Remembers Jean Vicks

Jean G. Vicks passed away on April 5, 2013 after her fourteen year battle with medullary thyroid cancer (MTC). She was 49. The diagnosis of MTC in 1999 resulted in seven surgeries, two clinical trials and three additional chemotherapy regimens in her desire to be well. Jean was honored as the inspiration for ITOG at the ITOG Annual Meeting at the Mayo Clinic in April. Jean's grace, selflessness and enthusiasm in the face of overwhelming challenges are an inspiration to all who knew her.

After graduation from Miss Porter's School, Jean attended the University of Virginia, where she played varsity field hockey, majored in French and International Relations, and earned a Bachelor of Arts with Distinction in 1985. She joined The Bank of New York in New York City and soon became a corporate lending officer. It was here that Jean met her husband, Dwight Vicks; the two were wed on June 13, 1987. Jean was an officer in the private lending division of Chemical Bank before the couple moved to Ithaca, NY, where she worked in Alumni Affairs and Development at Cornell University. With the birth of her twins, Sara Jane and Dwight Hatfield in 1991, Jean devoted her energies to raising her children. Her youngest, Emily Kathryn, was born in 1994.

The desire to give back and her passion for field hockey led Jean to a second career as coach and mentor to dozens of young women. She coached at New Hartford, Whitesboro and Clinton High Schools, and the USFA Futures program. The Section 3 coaches and referees honored Jean by dedicating the 2010 Section 3 Field Hockey tournament to her. She had the privilege of coaching her daughters Sara and Emily. Exercise was one of Jean's passions, including the Masters Swim Program at Hamilton College, Swim Across America, numerous triathlons and the Boilermaker Road Race. She loved biking, cross-country skiing and walking her dogs either at the Bridgehampton Beach or the Root Glen at Hamilton College. Jean's strong faith was in evidence as a member of St. James Episcopal Church in Clinton, NY, where she sang in the choir.

Dwight Vicks, Michael Ruane, Dr. Steve Sherman, Elizabeth Ruane, and Dr. Lori Wirth at the TA Associates Realty Charitable Golf Tournament in July.

TA Associates Realty Selects ITOG as Charitable Beneficiary

TA Associates Realty is one of the leading investors in commercial real estate in the United States. Michael Ruane, a founding member of TA Associates Realty, created an event to provide a valuable business gathering, golf at exceptional courses and raise funds to donate to worthy charities selected by the TA Associates team. ITOG was selected as the 2013 Charitable Beneficiary for the event held on July 29th. The day began with an informative business forum including a round table of leading executives from across the country. After lunch, participants played the historic Blue Hill Country Club near Boston.

Michael’s wife Elizabeth has Hürthle Cell Carcinoma, a rare form of thyroid cancer. Through their journey to obtain the best treatment options, they have consulted and work with ITOG member physicians. The Ruane’s believe in the mission of ITOG. Michael and Elizabeth have experienced first hand the outstanding work of ITOG, and the hope it provides thyroid cancer patients with challenging diagnoses.

Michael Ruane introduced ITOG Chair Dr. Steve Sherman, Secretary Dr. Lori Wirth and Treasurer Dwight Vicks who shared with the 350 attendees background of ITOG and the exciting achievements that continue to build. The membership of ITOG is most grateful for the generous support of the Ruane family and TA Realty Associates.

Dwight Vicks, Michael Ruane, Dr. Steve Sherman, Elizabeth Ruane, and Dr. Lori Wirth at the TA Associates Realty Charitable Golf Tournament in July.